119-HR-4993 Working Poor Impact Perspective

Summary of my opinion of H.R. 4993

As someone watching every dollar, this bill mostly helps regular families who have a parent or spouse on Medicare and need recurring infusions. It broadens Medicare’s definition so more external infusion pumps and their drugs count as DME for home use, which unlocks Part B coverage of the pump/supplies and ensures professional home‑infusion services are covered—reducing the hidden bills that currently pop up when drugs fall under Part D but supplies/services don’t. It would start the first calendar quarter at least a year after enactment; on Dec 10, 2025 the bill cleared a key committee vote 41–0. Net: favorable, with some guardrails needed. [1]Congress.gov — Text - H.R.4993: Joe Fiandra Access to Home Infusion Act of 2025[7]LII / Cornell Law — 42 CFR §414.202 – DME definition (includes “appropriate for…[4]CMS — Home Infusion Therapy/Home IVIG Services – program overview[8]National Home Infusion Association — NHIA Home Infusion Drug List (notes Medica…[2]Congress.gov — All Actions - H.R.4993 (119th): Committee action 12/10/2025

• What it changes: Treats certain external infusion pumps, associated home‑infusion drugs, and supplies as meeting the “appropriate for use in the home” DME requirement if clinical and supervision criteria are met (including ≥12 infusions/year), making them eligible for Part B coverage. [1]Congress.gov — Text - H.R.4993: Joe Fiandra Access to Home Infusion Act of 2025
• When it would start: The first calendar quarter beginning on or after one year post‑enactment. [1]Congress.gov — Text - H.R.4993: Joe Fiandra Access to Home Infusion Act of 2025
• Where it stands now: Ordered to be reported (amended) by Ways & Means on December 10, 2025, 41–0. [2]Congress.gov — All Actions - H.R.4993 (119th): Committee action 12/10/2025

Specific impacts I care about

I’m judging this by what it does to monthly bills, time off work, and fairness between patients and big players.

1. Household medical bills (near‑term): If your family member’s infusion shifts into Part B DME, you face the standard 20% coinsurance (after the Part B deductible) for pumps/supplies—and the related home‑infusion professional services are covered under the home infusion therapy benefit when the drug is delivered via a DME pump. That’s simpler and often cheaper than today’s patchwork where Part D may cover the drug but not supplies/services. [3]Medicare.gov (CMS) — Medicare.gov – Infusion pumps & supplies coverage and costs[4]CMS — Home Infusion Therapy/Home IVIG Services – program overview[8]National Home Infusion Association — NHIA Home Infusion Drug List (notes Medica…
2. Household medical bills (Part D interplay): Starting in 2025, Part D out‑of‑pocket drug costs are capped at $2,000 with an option to spread payments monthly. For cases where the drug would have been under Part D, the new cap helps; but the bill may move some cases to Part B coinsurance instead. The net for any given family will depend on drug price, Medigap/MA coverage, and whether supplies/nursing would otherwise be out‑of‑pocket. [5]CMS — CMS Fact Sheet – 2025 Medicare Advantage & Part D improvements (includes…
3. Time and travel: More treatment at home means fewer drives to hospital infusion suites—less missed work and gas/parking, which matters for caregivers juggling shifts. GAO and other analyses have long noted home infusion can be less costly than facility care, aligning patient convenience with potential system savings. [9]U.S. GAO — GAO-10-426 – Home Infusion Therapy: differences between Medicare and…
4. Fairness for patients vs. providers: Today, Medicare often covers pumps/drugs but not the professional services unless strict DME rules are met; Part D may cover drugs but not supplies/services. Expanding DME eligibility plus explicit cost‑sharing comparisons in the bill reduces “gotcha” bills for patients and curbs cost‑shifting to families. [4]CMS — Home Infusion Therapy/Home IVIG Services – program overview[8]National Home Infusion Association — NHIA Home Infusion Drug List (notes Medica…[1]Congress.gov — Text - H.R.4993: Joe Fiandra Access to Home Infusion Act of 2025
5. Small providers and access: By clarifying eligibility and tying coverage to qualified home‑infusion suppliers under supervision, the bill should stabilize reimbursements for community infusion pharmacies and nursing teams, which can improve local access for seniors. [4]CMS — Home Infusion Therapy/Home IVIG Services – program overview
6. Budget risk to me via premiums/taxes: More Part B coverage could raise Part B spending at the margin; improper billing in DMEPOS has been a recurring issue (though improving), so CMS/OIG oversight will matter to prevent waste that could boomerang into higher premiums. [6]HHS OIG — OIG Report (2025) – $22.7M improper DMEPOS payments during inpatient…

• Social impact (caregivers, rural/low‑mobility): Home‑based care reduces travel burdens and exposure risks, helping vulnerable patients and working caregivers balance shifts and appointments. GAO notes home infusion can substitute for more expensive settings without harming quality when appropriate. [9]U.S. GAO — GAO-10-426 – Home Infusion Therapy: differences between Medicare and…
• Environmental nudge: Fewer round‑trips to facilities modestly cuts fuel use—small, but positive—especially for frequent (≥12/year) infusions. [1]Congress.gov — Text - H.R.4993: Joe Fiandra Access to Home Infusion Act of 2025
• Transparency: The bill requires HHS to notify patients about cost‑sharing differences between home infusion and other settings—useful for real‑world budgeting before choosing a site of care. [1]Congress.gov — Text - H.R.4993: Joe Fiandra Access to Home Infusion Act of 2025

• Short‑term: Little immediate change until at least one year post‑enactment; families should still budget for 20% Part B coinsurance and use the 2025 Part D $2,000 cap and monthly payment option where relevant. [3]Medicare.gov (CMS) — Medicare.gov – Infusion pumps & supplies coverage and costs[5]CMS — CMS Fact Sheet – 2025 Medicare Advantage & Part D improvements (includes…
• Long‑term: More predictable costs and fewer surprise supply/nursing bills as more regimens qualify under Part B DME + home‑infusion services; potential system savings from site‑of‑care shifts if oversight prevents abuse. [4]CMS — Home Infusion Therapy/Home IVIG Services – program overview[9]U.S. GAO — GAO-10-426 – Home Infusion Therapy: differences between Medicare and…

• Unintended consequences: • Supplier gaming or upcoding without tight audits • Small increases in Part B spending/premiums if utilization jumps • Confusion during the transition (Part B vs Part D) unless HHS’ cost‑sharing notice is clear and standardized. [6]HHS OIG — OIG Report (2025) – $22.7M improper DMEPOS payments during inpatient…[1]Congress.gov — Text - H.R.4993: Joe Fiandra Access to Home Infusion Act of 2025

Bottom line

From a household‑budget lens, I view H.R. 4993 favorably.

• Why favorable: It closes a real coverage gap that’s been sticking patients with non‑drug costs, aligns coverage with how care is actually delivered at home, and bakes in patient cost‑sharing transparency. [8]National Home Infusion Association — NHIA Home Infusion Drug List (notes Medica…[4]CMS — Home Infusion Therapy/Home IVIG Services – program overview[1]Congress.gov — Text - H.R.4993: Joe Fiandra Access to Home Infusion Act of 2025
• What I’ll watch: Enforcement against DMEPOS overbilling and clear guidance on when an infusion falls under Part B vs Part D so families can plan and avoid surprise bills. [6]HHS OIG — OIG Report (2025) – $22.7M improper DMEPOS payments during inpatient…

• Key guardrails I’d ask Congress/HHS to add in rulemaking: • Pre‑payment edits for infusion pumps/supplies • Public dashboards on denials/overpayments • A standardized, plain‑English cost‑comparison notice for beneficiaries choosing home vs facility infusions. [6]HHS OIG — OIG Report (2025) – $22.7M improper DMEPOS payments during inpatient…[1]Congress.gov — Text - H.R.4993: Joe Fiandra Access to Home Infusion Act of 2025